ReviewJournal of nephrology2025
Approach to the prevention of atypical hemolytic uremic syndrome recurrence using eculizumab in a pregnant kidney transplant recipient with complement factor H gene mutation: a case report and literature review.
Review in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global change through regional policy-green nephrology in action.Journal of nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eculizumab, a monoclonal antibody targeting C5, is used to treat atypical hemolytic uremic syndrome (aHUS) and prevent recurrence post-kidney transplant (KTx). However, clinical experience with its use during pregnancy in kidney transplant recipients remains limited. We report a case of a 36-year-old woman with a history of aHUS and a high-risk complement factor H gene mutation who received a KTx and was treated with maintenance eculizumab post-transplant for the prevention of aHUS recurrence, and who later became pregnant. Eculizumab maintenance was continued during pregnancy. The patient delivered a healthy infant who developed normally; allograft function was well-preserved with no recurrence of thrombotic microangiopathy during pregnancy or in the 8 years postpartum. We reviewed the literature for similar cases and herein propose a structured approach to managing pregnant KTx recipients with a history of aHUS receiving eculizumab.
Indexed as
Identifiers
40646418What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.